Press Releases

Date	Title and Summary	View
Jun 07, 2018	Agile Therapeutics, Inc. Provides Corporate Update and Revised Cash Guidance Cash Expected to Enable Company to Fund Operations into Second Quarter 2019 PRINCETON, N.J. , June 07, 2018 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. , (Nasdaq:AGRX), a women’s healthcare company, today announced several key corporate updates: Formal dispute resolution request has been submitted
May 18, 2018	Agile Therapeutics, Inc. Provides Regulatory Update on Twirla® (AG200-15) for the Prevention of Pregnancy PRINCETON, N.J., May 18, 2018 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (Nasdaq:AGRX), a women's healthcare company, today announced the content of the official minutes from its Type A meeting with the U.S. Food and Drug Administration (FDA) held on April 16, 2018 to discuss the complete
May 07, 2018	Agile Therapeutics Reports First Quarter 2018 Financial Results Current Business Plan Expected to Enable Cash to Fund Operations through the end of 2018
Mar 14, 2018	Abstract on AG200-15 (Twirla®) Accepted for Presentation at the APhA 2018 Annual Meeting & Exposition PRINCETON, N.J., March 14, 2018 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (Nasdaq:AGRX), a women's healthcare company today announced that an abstract related to the Phase 3 SECURE study for AG200-15 (Twirla ® ), an investigational, once-weekly, low-dose hormonal contraceptive patch, has been
Mar 12, 2018	Agile Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results Current Business Plan Expected to Enable Cash to Fund Operations through the end of 2018
Dec 22, 2017	Agile Therapeutics, Inc. Receives a Complete Response Letter from the FDA for Twirla® (AG200-15) for the Prevention of Pregnancy PRINCETON, N.J., Dec. 22, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (NASDAQ:AGRX), a women's healthcare company, today announced that the U.S. Food and Drug Administration (FDA) issued a complete response letter (CRL) in response to the New Drug Application (NDA) resubmission for the
Nov 06, 2017	Agile Therapeutics Reports Third Quarter 2017 Financial Results Cash Expected to Fund Operations into Q2 2018 Prescription Drug User Fee Act (PDUFA) Goal Date for Twirla® is December 26, 2017 PRINCETON, N.J., Nov. 06, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women's healthcare company, today reported financial results for the three and
Oct 31, 2017	Agile Therapeutics Presents Additional Phase 3 SECURE Trial Results for Twirla® at the American Society for Reproductive Medicine (ASRM) Scientific Congress & Expo 2017 Data Suggests Twirla May Decrease Mean Length of Bleeding and Spotting Episodes
Oct 16, 2017	Agile Therapeutics Presents Additional Twirla® Phase 3 SECURE Study Results at NAFFP 2017 Detailed Bleeding Profile Data Provide Helpful Information for Patient Counseling PRINCETON, N.J., Oct. 16, 2017 – Agile Therapeutics, Inc., (NASDAQ: AGRX), a women’s healthcare company, today announced the presentation of additional results from the Phase 3 SECURE trial of its investigational
Oct 10, 2017	Agile Therapeutics Inc. Hosts First Analyst Day Focused on Previewing its Corporate Vision and Commercial Strategy Company Also Announces Four New Patents Granted for its Novel Transdermal Contraceptive Dosing Regimens